Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Secondary Lymphoid Organs

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

4D-Printed PLA/PEG/Mg Gyroid Metamaterial Scaffolds: Mechanistically Tunable Degradation and Body-Safe Shape Transformation.

Biomacromolecules·2026

Same author

Green Synthesis of ZnO and Mg-doped ZnO Nanoparticles Using Ferulago angulata Plant Extract and Its Effect on Second-Degree Burn Wound Healing.

Cell biochemistry and function·2025

Same author

Sex-Dependent Paracrine Effect of Conditioned Media From Adipose Tissue Derived Mesenchymal Stem Cells on Prostate Cancer Cells.

Journal of cellular and molecular medicine·2025

Same author

Burden of six common sexually transmitted infections groups in North Africa and Middle East Region from 1990 to 2021: A systematic analysis of global burden of diseases.

Journal of infection and public health·2025

Same author

Enhancing water deficit tolerance in canola (Brassica napus L.) through the synergistic application of nano-silicon and sulfur.

BMC plant biology·2025

Same author

Innovative microfluidic model for investigating the intestinal mucus barrier: numerical and experimental perspectives.

Drug delivery and translational research·2025

Search research articles

Related Experiment Video

Updated: Sep 2, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Clinical Post-Transplant Lymphoproliferative Disorders.

Ziba Aghsaeifard¹, Reza Alizadeh²

¹Department of Internal Medicine, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Cardiovascular & Hematological Disorders Drug Targets

|August 5, 2022

Summary

Post-transplant lymphoproliferative disorders (PTLDs) involve B-cell hyperproliferation after transplants, often linked to Epstein-Barr virus (EBV). Treatment strategies for PTLDs vary, including reduced immunosuppression and targeted therapies.

Keywords:

Epstein-Barr virus (EBV)hematopoietic stem cell immunosuppression lymphoma post-transplant lymphoproliferative disorders (PTLD)transplant recipients

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Related Experiment Videos

Last Updated: Sep 2, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Area of Science:

Immunology
Oncology
Transplantation

Background:

Post-transplant lymphoproliferative disorders (PTLDs) are a serious complication following solid organ or hematopoietic stem cell transplantation.
PTLDs are characterized by the uncontrolled proliferation of B lymphocytes, often associated with Epstein-Barr virus (EBV) infection.
Aggressive immunosuppressive therapy is a significant risk factor contributing to PTLD development.

Approach:

This review synthesizes current knowledge on PTLD pathogenesis, risk factors, and prevention strategies.
It examines the diverse histological classifications of PTLDs.
The review discusses various therapeutic modalities available for managing PTLDs.

Key Points:

PTLDs arise from B-cell hyperproliferation post-transplant.
Epstein-Barr virus (EBV) positivity is common in PTLD patients.
Histological findings categorize PTLDs into four distinct types.

Conclusions:

Effective management of PTLDs requires a comprehensive understanding of their pathogenesis and risk factors.
Therapeutic options for PTLDs are multifaceted, including immunosuppression modulation, antiviral agents, monoclonal antibodies, chemotherapy, and radiotherapy.
Tailoring treatment based on disease characteristics and stage is crucial for successful outcomes in PTLD patients.